In last trading session, Athira Pharma Inc (NASDAQ:ATHA) saw 1.66 million shares changing hands with its beta currently measuring 2.99. Company’s recent per share price level of $0.32 trading at -$0.01 or -3.05% at ring of the bell on the day assigns it a market valuation of $12.42M. That closing price of ATHA’s stock is at a discount of -1046.88% from its 52-week high price of $3.67 and is indicating a premium of 6.25% from its 52-week low price of $0.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.31 million shares which gives us an average trading volume of 220.40K if we extend that period to 3-months.
For Athira Pharma Inc (ATHA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Athira Pharma Inc (NASDAQ:ATHA) trade information
Upright in the red during last session for losing -3.05%, in the last five days ATHA remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $0.32 price level, adding 16.23% to its value on the day. Athira Pharma Inc’s shares saw a change of -45.80% in year-to-date performance and have moved -9.19% in past 5-day. Athira Pharma Inc (NASDAQ:ATHA) showed a performance of -29.65% in past 30-days. Number of shares sold short was 0.89 million shares which calculate 4.3 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 18 to the stock, which implies a rise of 98.22% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 33. It follows that stock’s current price would drop -837.5% in reaching the projected high whereas dropping to the targeted low would mean a loss of -837.5% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -73.94% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 70.77% while estimates for its earnings growth in next 5 years are of 72.93%.
Athira Pharma Inc (NASDAQ:ATHA)’s Major holders
Insiders are in possession of 2.90% of company’s total shares while institution are holding 51.72 percent of that, with stock having share float percentage of 53.27%. Investors also watch the number of corporate investors in a company very closely, which is 51.72% institutions for Athira Pharma Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at ATHA for having 5.4 million shares of worth $14.32 million. And as of 2024-06-30, it was holding 14.0776 of the company’s outstanding shares.
The second largest institutional holder is BAKER BROS. ADVISORS LP, which was holding about 3.15 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.2174 of outstanding shares, having a total worth of $8.36 million.
On the other hand, Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.49 shares of worth $0.47 million or 3.82% of the total outstanding shares. The later fund manager was in possession of 1.07 shares on Dec 31, 2024 , making its stake of worth around $0.34 million in the company or a holder of 2.75% of company’s stock.
